You are here

VIROGENOMICS, INC.

Company Information
Address
12909 SW 68th Parkway
TIGARD, OR -
United States



Information

UEI: N/A

# of Employees: N/A


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. A Novel Intervention Strategy for Stroke with RTL Therapy

    Amount: $1,350,283.00

    DESCRIPTION (provided by applicant): This application is a Phase II STTR to further the study of a novel therapeutic intervention for ischemic stroke. Phase I investigated the mechanism of protection ...

    STTRPhase II2012Department of Health and Human Services National Institutes of Health
  2. SBIR Phase II: Electronic Allergy Diagnostics: Photo-Immobilization as a General Strategy for Attaching Structurally and Compositionally Diverse Ligands onto a Single Support

    Amount: $489,496.00

    This Small Business Innovation Research (SBIR) Phase II project aims to create better diagnostic testing for drug, food, and environmental allergies. If successful, it would be transformative in the c ...

    SBIRPhase II2012National Science Foundation
  3. Electrochemical diagnostics for rapid, multiplexed detection of RA biomarkers

    Amount: $281,496.00

    DESCRIPTION (provided by applicant): Virogenomics is currently developing a portable, electrochemical device for rapid disease diagnosis of multiple indications. The basis of our approach is a patent ...

    SBIRPhase I2012Department of Health and Human Services National Institutes of Health
  4. SBIR Phase I:Electronic allergy diagnostics: Photo-immobilization as a general strategy for attaching structurally and compositionally diverse ligands onto a single support

    Amount: $179,992.00

    This Small Business Innovation Research (SBIR) Phase 1 project aims to rapidly address the feasibility of using photochemical linkers to immobilize small molecules, synthetic peptides, purified protei ...

    SBIRPhase I2010National Science Foundation
  5. Development of a plant-grown subunit vaccine against respiratory syncytial virus

    Amount: $581,068.00

    DESCRIPTION (provided by applicant): Respiratory syncytial virus (RSV)-caused disease represents a significant health care burden worldwide. The RSV infects virtually all children throughout the worl ...

    SBIRPhase I2010Department of Health and Human Services National Institutes of Health
  6. Novel RTL treatment to promote brain repair and cognitive recovery following meth

    Amount: $173,244.00

    DESCRIPTION (provided by applicant): Methamphetamine (MA) dependence is associated with neuropsychiatric side effects that make the addiction extremely challenging to treat. Patients seeking treatment ...

    STTRPhase I2010Department of Health and Human Services National Institutes of Health
  7. A Novel Approach to Stroke Treatment: Acid-Sensing Iion Channel Inhibitors

    Amount: $118,342.00

    DESCRIPTION (provided by applicant): Stroke is the third leading cause of death and a leading cause of serious, long-term disability in the United States. Although in recent years enormous progress ha ...

    STTRPhase I2009Department of Health and Human Services National Institutes of Health
  8. A Novel Intervention Strategy for Stroke with RTL Therapy

    Amount: $169,943.00

    DESCRIPTION (provided by applicant): Human stroke results in multi-organ systemic disease, rather than in solely a brain lesion. While patients may survive the initial brain insult, many succumb to CN ...

    STTRPhase I2009Department of Health and Human Services National Institutes of Health
  9. Recombinant T Cell Receptor Ligands for Treatmentof Uveitis

    Amount: $757,363.00

    DESCRIPTION (provided by applicant): Uveitis is a group of inflammatory eye diseases that is a major cause of visual loss in the working age group. It is currently estimated that each year in the Unit ...

    STTRPhase II2009Department of Health and Human Services National Institutes of Health
  10. Development of Novel Small Molecule Flavivirus Inhibitors

    Amount: $605,091.00

    DESCRIPTION (provided by applicant): We have identified TYT-1 as a novel sultam thiourea inhibitor of West Nile virus (WNV) replication. The compound has a 50% effective concentration (EC50) of 0.7 mi ...

    STTRPhase I2009Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government